Research on McBride plc (MCB:LON)  from Equity Development

Cost inflation delays margin recovery. Persistent input cost inflation, driven by sustained geo-political tensions, has further delayed McBride’s margin recovery. The Board now expects margins to recover towards previous levels during Q4 2027 (previously Q2 2027). FY27E guidance 20%–25% below consensus. Management now expects FY27E Adj. EBITA of c.£47m–£50m. We reduce our FY27E Adj. EBIT by 21.5% to £48.4m and Adj. PBT by 27% to £35.4m, and prudently reduce FY28E and FY29E Adj. PBT by 15% and 12% respectively. Strategic position remains robust. Economic pressure means private label products remain in demand, and McBride’s strategic momentum has continued with product innovation and structural cost savings. The Eurotab acquisition and the Vestacy contract manufacturing partnership are both earnings enhancing, and their integrations are on track. Fair Value cut 13% to 230p. We reduce our Fair Value to 230p per share (c.11x cal 2027 PER). We believe McBride’s market leadership strength and high ROCE are not fully appreciated in its rating.

View Full Research